Kornimate/medical-research-clean huggingface dataset:
effects of tdcs and physical therapy in chronic migraine

Conditions: Migraine Disorders

Summary: the aim of this clinical study is to compare the effects of tdcs, physiotherapy, and their association with the intensity in women with chronic migraine. for this purpose, the patients included in the study will be distributed among four groups following a factorial model.

a factorial, randomized clinical trial will be conducted to evaluate pain control, the number of migraine attacks, quality of life, emotional dysfunctions, and attentional processing of migraine patients. clinical outcomes will be evaluated through (i) a visual analog scale (vas); (ii) pressure pain threshold; (iii) a headache impact test (hit-6); (iv) a migraine disability assessment (midas); (v) short-form health survey questionnaire de 36 items (sf-36); (vi) patients' global impression of change scale (pgics); (vii) beck depression inventory (bdi); (viii) state-trait anxiety inventory (s-tai); (ix) perceived stress scale (pss); and (x) facial expression database.

Eligibility criteria:
inclusion criteria: * women; * 18-50 years old; * with chronic migraine according to ichd-3 beta; * literate; * stable on routine medications specific for mc for at least 2 months, who were not undergoing other types of non-pharmacological interventions for mc, not lactating or pregnant, without neurological diseases or serious neuropsychiatric diseases, without other types of associated headaches, without signs and/or symptoms of spinal radiculopathy, without metal implants located in the head and/or cochlear implants. exclusion criteria: * who perhaps become pregnant during the execution of the clinical trial * present some disease that disables their continuity in the treatment * start another type of treatment * show changes in physical activity and/or eating routine during the research * has severe depression (bdi \> 35).

Keywords: physical therapy transcranial direct current stimulation facial recognition
comparing an adductor fatigue strength test with handheld dynamometry

Conditions: Groin Injury; Groin Strain

Summary: the strength of the adductor muscles in a population of federated athletes will be measured using two tests: first, the maximum strength test, utilizing handheld dynamometry. subsequently, endurance strength will be measured with the adductor fatigue test (brazilian adductor performance test), in order to evaluate a possible correlation between the two tests.

the strength of the adductor muscles in a population of federated athletes will be measured using two tests: first, the maximum strength test, utilizing dynamometry, where the subject will perform a maximal isometric contraction against the resistance provided by the investigator. subsequently, endurance strength will be measured with the adductor fatigue test (brazilian adductor performance test), the participant must perform an adductor exercise as many repetitions as possible until exhaution. in order to evaluate a possible correlation between the two tests and thus, by performing one of them, obtain the results of the other variable. apart from the strength measurements, democraphic caracteristics will be recorded to assess possible correlations between studied variables.

Eligibility criteria:
inclusion criteria: * having an active lifestyle * competing at any level in a federated sports discipline. exclusion criteria: * not consenting to participate in the research. * being unable to understand or write in spanish. * having sustained any type of injury to the inguinal musculature in the past 3 months.

Keywords: injury prevention strength assessment
continuous positive airway pressure in sleep apnea syndrome: effects on metabolic syndrome and cardiac damage

Conditions: Sleep Apnea Syndrome; Metabolic Syndrome; Cardiac Remodelling; Continuous Positive Airway Pressure Ventilation

Summary: to assess in moderate to severe obstructive sleep apnea the effects of one year therapy with nighttime continuous positive airway pressure ventilation on the prevalence of metabolic syndrome and cardiovascular damage.


Eligibility criteria:
inclusion criteria: * moderate to severe sleep apnea syndrome exclusion criteria: * cardiovascular diseases (coronary artery disease, stroke, peripheral artery disease) * thyroid diseases * diabetes

Keywords: sleep apnea syndrome metabolic syndrome cardiac remodelling continuous positive airway pressure ventilation
comparative effectiveness of bariatric surgery versus medical management to induce diabetes remission in diabetic patients with bmi 30-35

Conditions: Diabetes

Summary: specific aims \& hypothesis primary aim: to evaluate laparoscopic bariatric surgery versus intensive medical weight management on indices of insulin resistance and resolution of type 2 diabetes among patients with bmi 30-35. hypothesis: bariatric surgery is the most effective treatment to induce diabetes remission in obese diabetic patients bmi 30-35. the primary outcomes will be assessed at 6 months: (1) within-patient change in insulin resistance after either bariatric surgery or initiation of intensive medical weight management, and (2) remission of diabetes, (i.e., fasting glucose \<126mg/dl and glucose \<200mg/dl two hours after a standard 75g oral glucose load without the use of anti-hyperglycemic medications). insulin resistance will be assessed at randomization and at 6 months with the homeostatic model assessment of insulin resistance (homa ir) based on insulin and fasting glucose, as well as oral glucose tolerance tests with area-under-the-curve (auc) measurement for insulin values. medication discontinuation will be derived from electronic health records and patient self-report at 6 months. secondary outcomes will include changes in hba1c, weight, blood pressure, waist circumference, and levels of fasting lipids.


Eligibility criteria:
inclusion criteria: patients eligible for study are adults (age ≥ 18) with type 2 diabetes who have a bmi 30-35, and are insured by metroplus insurance, but otherwise meet nih consensus criteria specifically (1) overweight for at least 5 years, (2) failure to lose weight with non-surgical means, (3) absence of medical or psychological contraindications, and (4) patient understanding of the procedure and its risks, and strong motivation to comply with the post-surgical regimen. patients must have permission from their physician to participate in the study. exclusion criteria: exclusions include being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks), participation in other obesity- or diabetes-related clinical trials, or diagnosis of cognitive dysfunction or significant psychiatric comorbidity.

Keywords: bariatric surgery diabetes sleeve gastrectomy gastric bypass gastric banding
color dental alteration caused by endodontic treatment

Conditions: Endodontically Treated Teeth; Tooth Discoloration; Root Canal Infection

Summary: the color change of endodontically treated teeth is a common concern in clinical practice. the objective of this study will be to evaluate, in vivo, the color change (δe00) caused by endodontic treatment. a randomized clinical trial (rct) will be conducted with the objective of evaluating δe00 originated from epoxy resin (ah plus) and mineral trioxide aggregate (mta fillapex) endodontic sealers, sectioned at the cervical level and 2 mm below, in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.

the sample syze determined that 48 anterior teeth (incisors and canines) and posterior teeth (premolars) should be included in the study. the sealer and cut will be randomly determined at time of endodontic treatment, originating four groups (n = 12): ah plus-cervical, mta fillapex-cervical, ah plus-2mm and mta-2mm. the endodontic access cavities will be sealed with resin composed of the color of the dental element. the mean, standard deviation and confidence interval (ci 95%) of the values of δe00 obtained for each sealer will be initially analyzed using the variable cut level (cervical or 2mm) using the t test. indeed, the values of δe00 will be analyzed by two-way analysis of variance, where the level of the cut and the type of sealer will be the factors under study.

Eligibility criteria:
inclusion criteria: endodontically treated tooth, without intraradicular retainer and fixation; * presence of homologous tooth to that treated, with pulp vitality and at least 1/3 of the crown; * correctly patient's file showing the endodontic treatment day, the endodontic filler used, the pulp condition at the first consultation, and periapical radiography, obtained with the use of a radiographic positioner, preserved and with a clear apical image exclusion criteria: * dental elements submitted to retreatment; * files with insufficient data, and absence of quality periapical radiography
phase 1b/2 trial of amg386 with pemetrexed and carboplatin in non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.

to evaluate the incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicity in subjects with metastatic non-squamous non-small cell lung cancer (nsclc) treated with amg 386 in combination with pemetrexed and carboplatin

Eligibility criteria:
inclusion criteria: * histologically confirmed, unresectable stage iv non-squamous non small cell lung cancer (nsclc) * radiographically evaluable disease (measurable or non-measurable) per recist 1.1 with modifications * adequate hematological, renal, and hepatic function, normal coagulation profile, calculated crcl ≥ 45 ml/min * other criteria may apply exclusion criteria: * any prior chemotherapy or targeted therapy for non-squamous nsclc * subjects with adenosquamous histology or any histology subtype containing greater than 10% squamous cells * subjects with an epidermal growth factor receptor (egfr) mutation sensitive to treatment with a tyrosine kinase inhibitor (tki) * subjects with known anaplastic lymphoma kinase (eml4-alk) translocations * history or presence of central nervous system metastases * central (chest) radiation therapy within 28 days prior to enrollment/randomization, radiation therapy to any other site(s) within 14 days prior to enrollment/randomization * history of pulmonary hemorrhage or gross hemoptysis within 6 months * history of arterial or venous thromboembolism within 12 months * history of clinically significant bleeding within 6 months * clinically significant cardiovascular disease within 12 months * other criteria may apply
feasibility of brachial plexus ultrasound in evaluation of patients with brachial plexus injuries

Conditions: Brachial Plexus Injury

Summary: evaluation of ultrasound as a diagnostic tool in assessment of patients with brachial plexus injuries before undergoing surgical exploration

ultrasound of the brachial plexus is particularly good for assessing brachial plexus injuries, nerve sheath tumors,perineural fibrosis, metastasis, some inflammatory neuropathies, neuralgic amyotrophy and post traumatic sequele

Eligibility criteria:
inclusion criteria: * all patients ages with brachial plexus injuries exclusion criteria: * patients underwent brachial plexus surgery before * patients with surgical emphysema * patients with serious skeletal malformations
2 doses of ferrlecit versus oral iron to treat iron-deficiency anemia in peritoneal dialysis patients.

Conditions: Iron Deficiency Anemia

Summary: this is a phase 3 clinical investigation. patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of ferrlecit or oral iron in a 1:1:1 ratio.


Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age. * received maintenance peritoneal dialysis therapy for at least 4 weeks. * was expected to remain on peritoneal dialysis therapy for duration of study. * had predetermined low hemoglobin and transferrin saturation (tsat) levels. * signed patient informed consent. exclusion criteria: * had a predetermined serum levels of ferritin and tsat * pregnant or lactating. * had a serious concomitant medical disorder incompatible with participation in the study. * had a known hypersensitivity to ferrlecit or any of its components. * unable to cooperate or comply with the protocol.

Keywords: anemia.
biomarkers for feeding intolerance in infants with complex congenital heart defects undergoing single ventricle staged palliation

Conditions: Single Ventricle Physiology

Summary: the purpose of this study is to investigates serum and stool biomarkers as predictors for post-operative feeding intolerance in infant patients with complex congenital heart defects who undergo single ventricle staged palliation surgery.


Eligibility criteria:
inclusion criteria: * full term gestational period (37 weeks gestation or greater) * minimum of 2.5kg or greater body weight * diagnosis of single ventricle physiology, or complex congenital cyanotic heart disease requiring staged palliation surgery in the form of norwood-type procedure, systemic-to-pulmonary artery shunt, or pulmonary artery banding. exclusion criteria: * have diseases affecting other organs, * have major congenital anomalies such as hirschsprung disease, imperforate anus, charge syndrome, or vacterl association.
baricitinib in symptomatic patients infected by covid-19: an open-label, pilot study.

Conditions: Pharmacological Action

Summary: there is no specific antiviral treatment recommended for covid-19, and no vaccine is currently available. baricitinib, an anti-janus kinase inhibitor (anti-jak) acting against jak1 and jak2. the drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the jak1- and jak2-mediated cytokine release. the drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.the evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate covid-19 infection receiving baricitinib combined with antiviral therapy.

study design. interventional, open-label, 2-week, prospective trial of a cohort of patients with mild to moderate covid-19 infection. objectives. primary. to assess the efficacy of baricitinib combined with antiviral therapy in patients with covid-19-related mild and moderate disease in terms of reduction of the percentage of subjects requiring icu admission. secondary objectives. to describe the clinical findings in a cohort of symptomatic covid-19-infected subjects; to investigate the role of crp, il-6, and tnfα levels as predictor of progression to ards; to assess the type and incidence of adverse events (aes).

Eligibility criteria:
inclusion criteria: * all consecutive patients with mild to moderate covid-19 infection * age \>18 years, * clinical diagnosis of covid19 infection * patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia. * all patients should be willing and able to provide written informed consent prior to performing study procedures. exclusion criteria: * age less than 18 * history of thrombophlebitis. * patient with latent tuberculosis infection (quantiferon test). * pregnancy and lactation.

Keywords: covid-19 baricitinib moderate disease infection
the clinical study on treating acute gouty arthritis using both internal and external therapy of tonifying spleen and descending turbid

Conditions: Acute Gouty Arthritis

Summary: this research is based on spleen trapped by dampness and turbid which is the pathogenesis of gouty arthritis.it uses effective prescription of endocrinology of dongzhimen hospital.in this study, the investigators use multi-center randomized parallel controlled clinical trials.the treatment groups are afforded oral traditional chinese medicine decoction-tonifying spleen and descending the turbid decoction as well as soaking and wet wrapping.the control groups are afforded diclofenac sodium enteric-coated tablets as a positive control drug.the outcome is evaluated by condition of symptoms remission,pain relief time, recurrence rate and laboratory index to determine the efficacy of internal and external treatment.and the research will provide optimized diagnosis and treatment program. the investigators hope this research will also get tonifying spleen and descending the turbid internal and external treatment for gouty arthritis effective clinical treatment.


Eligibility criteria:
inclusion criteria: 1. aged 18-75, and gender unlimited; 2. the patients must meet western medicine diagnostic criteria for acute gouty arthritis; 3. the patients must meet that integral syndrome differentiation conforms to the spleen beset by dampness syndrome and local syndrome differentiation conforms to blockage disease due to heat. exclusion criteria: 1. secondary hyperuricemia, such as cancer and perichemotherapy of leukemia, renal failure, cirrhosis of the liver and drug effect(such as diuretics, aspirin, antitubercular agents), et al. 2. acute infectious diseases, stroke, acute myocardial infarction ,as well as other acute diseases and tumors, rheumatoid arthritis. 3. patients with peptic ulcer and gastrointestinal bleeding.

Keywords: acute gouty arthritis tonifying spleen and descending the turbid soaking wet wrapping
improving outcomes in early menopause after cancer

Conditions: Early Menopause; Cancer

Summary: the goal of this study is to create and test a new program led by nurse navigators to help women who experience early menopause after cancer. the program includes personalized menopause education, decision support, and skills to manage menopause symptoms. the main questions it aims to answer are: 1. is the program easy to join, engaging, and well-received by participants? 2. does the program group show greater improvements in knowledge, decision-making, confidence, and menopause symptom management compared to the control group? participants will complete sessions of either the program being tested or an educational control program with a nurse navigator via video. participants will also complete questionnaires when they start the study and again about 10 weeks later.


Eligibility criteria:
inclusion criteria: * female (biological sex); * 18 to 44 years old; * completed cancer treatment (other than endocrine therapy) \>12 months prior to enrollment; * have not had a period for more than 12 months (amenorrhea); * able to speak and read english. exclusion criteria: * diagnosis of metastatic cancer; * visual or hearing impairment that would interfere with participation in study; * cognitive impairment or severe mental illness that would interfere with participation in study.
post vaccination adverse events in covid-19 vaccine recipients

Conditions: COVID-19 Vaccination; Vaccine Adverse Reaction

Summary: covid-19 pandemic is caused by severe acute respiratory syndrome corona virus 2 (sars-cov-2) since its outbreak 2019. protection against covid-19 can be achieved through global immunization. various vaccines for sars-cov-2 has been registered and approved for administration in humans. it is important to understand the safety and efficacy of vaccines during robust research to develop global immunity against sars-cov-2. this study aimed to collect data on post vaccination adverse events in regional population of district bahawalpur.

bahawalpur district of punjab province has population of 3.998 million and among these 2.6 million above 12 years of age are eligible for vaccination against sars-cov-2. 28 centers were established for vaccination within the districts at designated sites for covid-19 vaccination. 87% targeted population has been vaccinated till 15th february 2022. investigators designed this study to collect and evaluate data on adverse effects after vaccination of covid-19. investigators aimed to collect information through interviewing participants in general places of designated sites of vaccination centers established in district bahawalpur. history will be recorded from participants and in case of adverse events detailed available history will be recorded including following adverse effects from available records on following. * cardiovascular adverse effects * cerebrospinal adverse events * respiratory disturbances * hepatobiliary disorders * urogenital adverse effects * musculoskeletal adverse effect * psychological diseases * blood biomarkers changes * autoimmune adverse events * allergic reactions and hypersensitivity collected data will be summarized to get percentage of adverse effects in general population. recorded adverse events will be assessed for their frequency in participants and association with vaccination will be assessed through employing statistical methods. subsequent information on handling of adverse events will be recorded including * nature of adverse event * hospitalization and severity of adverse events * mortality / morbidity caused by vaccination * days of hospitalization * changes in blood biomarkers * interventions adopted for adverse events * diseased period * covid-19 infection positivity through rt-pcr / imaging for round glass opacities / covid-19 changes overall efficacy and safety of vaccination will be assessed through collected data.

Eligibility criteria:
inclusion criteria: age \>12 year vaccinated (single dose, double dose, booster dose) clinical diagnosis of allergic reactions and hypersentivity, cardiovascular diseases musculoskeletal diseases respiratory disease immunological disease kidney diseases exclusion criteria: age \<12 years of age not vaccinated history of disease before vaccination -

Keywords: covid-19 vaccination, inactivated vaccine, rna vaccine